A detailed history of Bank Of America Corp transactions in In8 Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 420 shares of INAB stock, worth $126. This represents 0.0% of its overall portfolio holdings.

Number of Shares
420
Previous 266 57.89%
Holding current value
$126
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.27 - $0.88 $41 - $135
154 Added 57.89%
420 $0
Q2 2024

Aug 14, 2024

BUY
$0.85 - $1.68 $226 - $446
266 New
266 $0
Q4 2023

Feb 14, 2024

BUY
$0.69 - $2.34 $8 - $30
13 New
13 $0
Q1 2023

May 12, 2023

BUY
$1.17 - $2.83 $21 - $50
18 Added 90.0%
38 $0
Q4 2022

Feb 10, 2023

BUY
$1.39 - $2.47 $27 - $49
20 New
20 $0
Q1 2022

May 16, 2022

SELL
$2.76 - $4.6 $19 - $32
-7 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$4.39 - $8.55 $30 - $59
7 New
7 $0

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $7.35M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.